Cochrane · systematic review · CD009883
Thrombopoietin mimetics for patients with myelodysplastic syndromes
Dodillet, H, Kreuzer, KA, Monsef, I, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 12.5%Ungraded 1 · 12.5%Very low 2 · 25%Low 2 · 25%Moderate 2 · 25%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Thrombopoietin mimetics compared to placebo for patients with myelodysplastic syndromes
Population: Adult patients with myelodysplastic syndromes and thrombocytopenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Thrombopoietin mimetics vs placebo | no estimate extracted | 2 studies · 282 participants | Ungraded |
Mortality during study Thrombopoietin mimetics vs placebo | RR 0.97 [0.73, 1.27] | 6 studies · 746 participants | Low Downgraded: imprecision |
Transformation to AML Thrombopoietin mimetics vs placebo | RR 1.02 [0.59, 1.77] | 5 studies · 372 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Incidence of bleeding events Thrombopoietin mimetics vs placebo | RR 0.92 [0.86, 0.98] | 5 studies · 390 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Transfusion requirement Thrombopoietin mimetics vs placebo | RR 0.83 [0.66, 1.05] | 4 studies · 358 participants | Low Downgraded: imprecision |
Health‐related quality of life Thrombopoietin mimetics vs placebo | no estimate extracted | NR | No studies |
All adverse events Thrombopoietin mimetics vs placebo | RR 1.01 [0.96, 1.07] | 5 studies · 390 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Serious adverse events Thrombopoietin mimetics vs placebo | RR 0.89 [0.54, 1.46] | 4 studies · 356 participants | Very low Downgraded: imprecision |